ECSP10010327A - Péptidos del fviii y su uso para hemofílicos tolerantes - Google Patents

Péptidos del fviii y su uso para hemofílicos tolerantes

Info

Publication number
ECSP10010327A
ECSP10010327A EC2010010327A ECSP10010327A ECSP10010327A EC SP10010327 A ECSP10010327 A EC SP10010327A EC 2010010327 A EC2010010327 A EC 2010010327A EC SP10010327 A ECSP10010327 A EC SP10010327A EC SP10010327 A ECSP10010327 A EC SP10010327A
Authority
EC
Ecuador
Prior art keywords
peptides
fviii
hemophylics
tolerant
peptide
Prior art date
Application number
EC2010010327A
Other languages
English (en)
Inventor
David Wraith
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Publication of ECSP10010327A publication Critical patent/ECSP10010327A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee un péptido que comprende una secuencia residual central derivable del FVIII humano, este péptido es capaz de unirse a una molécula de MHC de clase II sin un procesamiento de antígeno adicional. La presente invención también se refiere al uso de dichos péptidos para la prevención o supresión de la formación de anticuerpos inhibidores en la hemofilia A y/o hemofilia adquirida.
EC2010010327A 2007-12-04 2010-07-02 Péptidos del fviii y su uso para hemofílicos tolerantes ECSP10010327A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0723712.6A GB0723712D0 (en) 2007-12-04 2007-12-04 Peptides

Publications (1)

Publication Number Publication Date
ECSP10010327A true ECSP10010327A (es) 2010-09-30

Family

ID=38982965

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010327A ECSP10010327A (es) 2007-12-04 2010-07-02 Péptidos del fviii y su uso para hemofílicos tolerantes

Country Status (26)

Country Link
US (1) US8445448B2 (es)
EP (1) EP2227488B3 (es)
JP (2) JP5501245B2 (es)
KR (1) KR101519840B1 (es)
CN (2) CN101889024B (es)
AU (1) AU2008332968B2 (es)
BR (1) BRPI0820143A2 (es)
CA (2) CA2707559C (es)
CY (1) CY1115168T1 (es)
DK (1) DK2227488T6 (es)
EA (1) EA019370B1 (es)
EC (1) ECSP10010327A (es)
ES (1) ES2458315T7 (es)
GB (1) GB0723712D0 (es)
HK (1) HK1144292A1 (es)
HR (1) HRP20140344T4 (es)
IL (1) IL205780A (es)
MX (1) MX2010006084A (es)
MY (1) MY150995A (es)
NZ (1) NZ585217A (es)
PL (1) PL2227488T6 (es)
PT (1) PT2227488E (es)
SI (1) SI2227488T1 (es)
UA (1) UA101003C2 (es)
WO (1) WO2009071886A1 (es)
ZA (1) ZA201002997B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191063A1 (en) 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
KR101804136B1 (ko) * 2008-06-24 2017-12-04 옥타파마 아게 응고 인자 ｖｉｉｉ을 정제하는 방법
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
CA2765657A1 (en) * 2009-06-16 2010-12-23 Tokai University Anti-gram-negative bacteria agent
NZ609474A (en) * 2010-10-27 2015-06-26 Baxter Healthcare Sa Fviii peptides for immune tolerance induction and immunodiagnostics
EP3453402B1 (en) 2012-01-12 2021-07-21 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
LT2917232T (lt) * 2012-11-12 2017-06-26 Apitope International Nv Iš faktoriaus vii kilę peptidai, skirti naudoti hemofilijos gydymui
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
US20230126796A1 (en) * 2021-09-23 2023-04-27 University Of Utah Research Foundation Functional and therapeutic effects of par4 cleavage by cathepsin g

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015615A1 (en) 1989-06-20 1990-12-27 Scripps Clinic And Research Foundation The phospholipid binding domain of factor viii
BR9806793A (pt) * 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
US20030191063A1 (en) 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia
US7189830B2 (en) * 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
WO2002098454A2 (en) * 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
BR0308860A (pt) * 2002-04-18 2005-01-04 Merck Patent Gmbh Fator viii modificado
EP1729795B1 (en) * 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2006003183A1 (de) 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd A dry bandage containing thrombin and pectin

Also Published As

Publication number Publication date
CN103709234A (zh) 2014-04-09
MX2010006084A (es) 2010-06-23
EP2227488B3 (en) 2014-11-19
IL205780A (en) 2015-06-30
CY1115168T1 (el) 2016-12-14
DK2227488T6 (en) 2015-02-16
JP6063402B2 (ja) 2017-01-18
ES2458315T7 (es) 2015-02-18
PT2227488E (pt) 2014-04-21
IL205780A0 (en) 2010-11-30
CA2707559A1 (en) 2009-06-11
AU2008332968B2 (en) 2014-03-20
EP2227488A1 (en) 2010-09-15
GB0723712D0 (en) 2008-01-16
CA3005013A1 (en) 2009-06-11
DK2227488T3 (da) 2014-04-22
HK1144292A1 (en) 2011-02-11
EA019370B1 (ru) 2014-03-31
HRP20140344T4 (hr) 2015-07-31
US20100323966A1 (en) 2010-12-23
JP2014088440A (ja) 2014-05-15
SI2227488T1 (sl) 2014-06-30
HRP20140344T1 (en) 2014-05-09
EA201070681A1 (ru) 2010-10-29
EP2227488B1 (en) 2014-01-22
UA101003C2 (uk) 2013-02-25
US8445448B2 (en) 2013-05-21
ZA201002997B (en) 2011-07-27
JP5501245B2 (ja) 2014-05-21
ES2458315T3 (es) 2014-04-30
NZ585217A (en) 2012-11-30
CN101889024A (zh) 2010-11-17
JP2011505414A (ja) 2011-02-24
PL2227488T6 (pl) 2015-04-30
PL2227488T3 (pl) 2014-07-31
WO2009071886A1 (en) 2009-06-11
CN101889024B (zh) 2014-04-23
BRPI0820143A2 (pt) 2015-05-12
AU2008332968A1 (en) 2009-06-11
KR20100087346A (ko) 2010-08-04
CN103709234B (zh) 2017-01-18
MY150995A (en) 2014-03-31
CA3005013C (en) 2021-11-16
CA2707559C (en) 2018-07-03
KR101519840B1 (ko) 2015-05-18

Similar Documents

Publication Publication Date Title
ECSP10010327A (es) Péptidos del fviii y su uso para hemofílicos tolerantes
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
EA201592264A1 (ru) Композиции, которые индуцируют хелперное действие т-клеток
EA200701305A1 (ru) Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
MX2011011132A (es) Peptido auxiliar del antigeno del cancer.
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
MX2012003058A (es) Vacunas dirigidas a celulas de langerhans.
PE20142330A1 (es) Vacuna de peptido ch3 de ige
UA97092C2 (ru) T-клеточные эпитопы с раково-эмбрионального антиген-незрелого рецепторного белка ламинина и их медицинское применение
WO2009035412A8 (en) Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof
CY1114618T1 (el) Βιολογικα δραστικα πεπτιδια που περιεχουν καρβοξυτελικη αργινινη
NZ594198A (en) Neil3 peptides and vaccines including the same
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
CY1119164T1 (el) Πεπτιδια που προερχονται απο τον παραγοντα viii για χρηση στη θεραπεια της αιμορροφιλιας α
CO6460780A2 (es) Péptido
JP2014508098A5 (es)
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины
WO2009053535A3 (en) Peptide vaccine for influenza virus
TH130487B (th) เพปไทด์ที่อนุพัทธ์มาจากแฟคเตอร์ viii
EA200970834A1 (ru) Антитела к вирусу краснухи
TH130487A (th) เพปไทด์ที่อนุพัทธ์มาจากแฟคเตอร์ viii
EA201992367A1 (ru) Вакцины на основе пептидов, способы их изготовления и применения для индуцирования иммунного ответа
CY1117265T1 (el) Αντισωματα aνti-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων